Principles of Gynecologic Oncology Surgery

Pre-Op & Staging - Setting the Stage

• Initial Workup:
  • History, comprehensive physical exam (P/V, P/R).
  • Labs: CBC, KFT, LFT, Coagulation.
  • Tumor Markers: CA-125 (Ovary), CEA, AFP, $β-hCG$.
  • Performance status (ECOG/Karnofsky).
• Imaging for Staging:
  • USG (transvaginal/abdominal): First-line.
  • CT (C/A/P): Metastasis, nodal status.
  • MRI Pelvis: Local invasion (cervix, endometrium).
  • PET-CT: Equivocal findings, recurrence.
• Definitive Steps:
  • Biopsy: Histopathological diagnosis is mandatory.
  • Staging: Primarily FIGO (surgical), TNM.

    ⭐ Cervical cancer is clinically staged (FIGO), a key exception.

  • Counselling & informed consent.

Surgical Maxims - Scalpel Wisdom

• Primary Goal: Achieve R0 resection (microscopically negative margins). Complete tumor removal is paramount.
• Cytoreductive Surgery (Ovarian Cancer): Aim for optimal (<1 cm residual disease) or complete (no visible disease) cytoreduction.
  • Impacts prognosis significantly.
• Surgical Staging: Precise pathological staging is crucial; dictates adjuvant therapy.
• Minimize Morbidity: Balance radicality with quality of life; nerve-sparing techniques where feasible.
• Multidisciplinary Approach: Collaboration with medical/radiation oncologists, pathologists.
• Intraoperative Frozen Section: Guides surgical decisions, e.g., extent of lymphadenectomy, assessment of margins.
• En-bloc Resection: Remove tumor with clear margins, minimizing tumor spillage.

⭐ In advanced epithelial ovarian cancer, achieving no gross residual disease (R0) after primary cytoreductive surgery offers the best survival advantage, superior to optimal cytoreduction (<1 cm).

Key Procedures & Tech - Tools of Trade

• Key Surgical Procedures:
  • Hysterectomy: Total (TAH, TLH/LAVH), Radical (Wertheim's).
  • Salpingo-oophorectomy: Unilateral (USO) / Bilateral (BSO).
  • Lymphadenectomy: Pelvic (obturator, iliac), Para-aortic; Sentinel Node Biopsy (SLNB).
  • Cytoreductive Surgery (Debulking): Primary (PDS) or Interval (IDS). Aim for R0 (no visible disease).
  • Pelvic Exenteration: For select advanced/recurrent central pelvic disease.
• Minimally Invasive Surgery (MIS):
  • Laparoscopy & Robotic-assisted surgery.
  • Benefits: ↓blood loss, ↓pain, ↓hospital stay, faster recovery.
• Essential Tech:
  • Energy Devices: Ultrasonic (Harmonic), Advanced Bipolar (LigaSure).
  • Intraoperative Frozen Section: Guides surgical extent.
  • Intraoperative imaging (e.g., ultrasound for localization).

⭐ Optimal cytoreduction in advanced ovarian cancer (residual disease < 1 cm, ideally R0) significantly improves survival.

Post-Op & Palliation - Aftercare & Alternatives

• Post-Operative Care:
  • Early ambulation, DVT prophylaxis (LMWH, compression stockings).
  • Pain management: Multimodal approach.
  • Wound care; monitor drains for output & early removal.
  • Monitor for complications: SSI, VTE, ileus, hemorrhage.
• Palliative Interventions (Advanced/Recurrent Disease):
  • Goal: Symptom control, improve Quality of Life (QoL).
  • Palliative Surgery:
    • Relieve obstruction (e.g., bowel, ureteric).
    • Control bleeding or malignant discharge.
    • Symptomatic cytoreduction.
  • Non-Surgical: Palliative radiotherapy, chemotherapy, Best Supportive Care (BSC).

  ⭐ Secondary cytoreductive surgery in recurrent ovarian cancer is considered if platinum-sensitive, good performance status, and resectable disease, aiming for no residual disease.

High‑Yield Points - ⚡ Biggest Takeaways

• Preoperative assessment is vital: evaluate comorbidities, nutrition, and disease extent.
• Surgical staging is key for most gynecologic cancers, directing adjuvant treatment.
• Optimal cytoreduction (residual disease < 1 cm, ideally none) improves survival in advanced ovarian cancer.
• Radical hysterectomy with pelvic lymphadenectomy is standard for early cervical cancer.
• Sentinel lymph node (SLN) biopsy reduces morbidity in endometrial and vulvar cancers.
• ERAS protocols aim to ↓ complications and shorten hospital stays.